Business Overview: Omeros Corporation (NASDAQ: OMER)

---

Executive Summary

Omeros Corporation is a Seattle, Washington-headquartered biopharmaceutical company focused on the complement system — a branch of the innate immune system — along with select programs in oncology and addictive/compulsive disorders. For most of its public life Omeros was a clinical- and early-commercial-stage company funded primarily by sales of its ophthalmic surgery product OMIDRIA; that product was divested in late 2021, and for several years afterward the company's balance sheet was thin while it pushed its lead complement candidate, narsoplimab, through the FDA.

That changed through late 2025 and 2026. The FDA approved YARTEMLEA (narsoplimab-wuug) in December 2025 as the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a rare and often fatal complication of bone marrow transplant, and Omeros began direct U.S. commercial sales in January 2026. Almost simultaneously, Omeros sold global rights to its earlier-stage complement asset, zaltenibart (OMS906), to Novo Nordisk for a $240 million upfront payment plus up to roughly $1.8 billion in additional milestones. Omeros is now best understood as a newly commercial-stage, complement-focused specialty biopharma company that has converted two decades of complement-pathway research into one marketed orphan drug and one large pharma partnership, while retaining residual economics from OMIDRIA as a royalty stream.

Omeros matters disproportionately to its size because it holds a genuine first-in-class, orphan-indication monopoly in a disease with no other approved treatment, inside a complement-therapeutics field that has otherwise become crowded and highly competitive.

---

1. Core Business Model & How They Work

Omeros runs the standard orphan-drug biopharma model: discover a mechanistically differentiated therapeutic, drive it through a narrow, biomarker-defined patient population in clinical trials, obtain regulatory approval (often via a rare-disease/breakthrough pathway), and commercialize it directly to a small number of specialized treatment centers rather than through a broad primary-care sales force.

[ Complement-Pathway R&D ] ➡️ [ Orphan-Indication Clinical Trials ] ➡️ [ FDA/EMA Approval ] ➡️ [ Direct Specialty Sales Force ] ➡️ [ Transplant Center Adoption ] ➡️ [ Pipeline Monetization via Big Pharma Licensing ]

Key Operational Drivers

1. Narrow, high-severity target population: YARTEMLEA targets TA-TMA, which occurs in a minority of the roughly 20,000+ annual U.S. allogeneic stem-cell transplants. Omeros estimates that just ~80 of the ~175 U.S. transplant centers perform about 80% of procedures, letting a small, specialized sales force reach most of the addressable market directly rather than building broad primary-care infrastructure.
2. Platform re-use across the complement cascade: Omeros's two lead assets — narsoplimab (anti-MASP-2) and zaltenibart (anti-MASP-3) — both come from the same proprietary lectin-pathway/alternative-pathway complement research platform that the company has built over roughly two decades, letting it generate a pipeline of related candidates (OMS1029, a long-acting MASP-2 antibody, among them) from one scientific core.
3. "Build, then monetize" asset strategy: Rather than commercializing every complement asset itself, Omeros commercializes its most clinically mature, most defensible orphan asset (narsoplimab/YARTEMLEA) directly, while licensing out an earlier-stage, larger-indication asset (zaltenibart, aimed at PNH, a disease already served by multiple approved complement drugs) to a company with the global commercial scale to compete there — Novo Nordisk.
4. Legacy royalty tail: Although Omeros no longer commercializes OMIDRIA, the company retains a multi-year royalty and milestone stream from its 2021/2025-era divestiture, which continues to show up as discontinued-operations income and provides a non-dilutive cash cushion.

---

2. Business Segments

Omeros does not report distinct operating segments; it manages the business as a single biopharmaceutical enterprise. A segment breakdown would overstate structure that doesn't exist in the company's own reporting, so this section is omitted in favor of describing the business by program/product in the Product Portfolio section below.

---

3. Product Portfolio

---

4. Competitive Landscape

Omeros's commercial and pipeline competitive position splits cleanly along its two lead assets, both of which sit inside the broader complement-inhibitor therapeutic class.

            COMPLEMENT THERAPEUTICS POSITIONING
┌──────────────────────────────────────────────────────────┐
│ Narrow, orphan indication                                 │
│   ▲                                                        │
│   │  [YARTEMLEA]                                           │
│   │  (TA-TMA — no approved competitor)                      │
│   │                                                         │
│   │                    [Zaltenibart→Novo]                   │
│   │                    (PNH — many approved rivals)          │
│   │                                                          │
│   │                              [Soliris/Ultomiris - AstraZeneca]
│   │                              [Fabhalta - Novartis]
│   │                              [Empaveli - Apellis]
│   │                              [PiaSky - Roche]
│   ▼                              [Voydeya - AstraZeneca]
│ Broad, contested indication                                │
└──────────────────────────────────────────────────────────┘

TA-TMA (YARTEMLEA's market)

• Direct approved competitors: none. YARTEMLEA is currently the only approved treatment for TA-TMA.
• Off-label pressure: Physicians have historically used complement inhibitors approved for other indications — Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz), both AstraZeneca/Alexion products — off-label for TA-TMA. A pediatric Phase 3 trial of ravulizumab in TA-TMA missed its primary endpoint, and an adult Phase 3 trial has completed without results yet announced, leaving YARTEMLEA's labeled, on-mechanism position comparatively strong for now.
• Regulatory risk: Despite the clean U.S. competitive picture, the EU regulatory path has stalled (see Risks below), limiting near-term competitive exposure to the U.S. market for the time being.

PNH and broader alternative-pathway disease (zaltenibart's market, now Novo Nordisk's problem)

• Established players: AstraZeneca/Alexion (Soliris, Ultomiris, and the oral factor D inhibitor Voydeya/danicopan), Novartis (Fabhalta/iptacopan, oral), Apellis Pharmaceuticals (Empaveli/pegcetacoplan), and Roche (PiaSky/crovalimab-akkz).
• Dynamics: PNH already has multiple approved, well-reimbursed therapies spanning IV and oral formulations, making it a crowded, share-shift market rather than an open field — a key reason Omeros chose to license zaltenibart to a large, globally scaled partner rather than commercialize it alone.
• ChemoCentryx/Vifor's Tavneos (avacopan) also competes in adjacent complement-mediated indications, illustrating how broad the complement-inhibitor competitive set has become across autoimmune and hematologic disease.

---

5. Strategic Strengths & Risks

Strategic Strengths

• First-in-class, sole-approved-therapy status in TA-TMA: YARTEMLEA faces no approved on-label competitor in the U.S., a rare position for any newly launched drug and one that supports strong early pricing and adoption.
• Concentrated, reachable customer base: With roughly 80 transplant centers driving the large majority of U.S. TA-TMA cases, Omeros can achieve meaningful market coverage with a lean, specialized commercial organization rather than the large sales infrastructure a primary-care drug would require.
• Non-dilutive balance-sheet transformation: The $240 million Novo Nordisk upfront payment, growing YARTEMLEA sales, and the ongoing OMIDRIA royalty stream have turned Omeros from a going-concern-risk clinical company into one reporting GAAP net income in 2026 — a rare and recent inflection for a company of its size.
• Validated platform: Novo Nordisk's willingness to pay up to ~$2 billion in total deal value for zaltenibart is third-party validation of Omeros's underlying MASP-targeting complement research platform, beyond narsoplimab alone.

Strategic Risks

• European regulatory setback: The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on narsoplimab's EU marketing authorization in June 2026, and upheld that negative opinion following re-examination in October 2026. Omeros is now winding down its EU compassionate-use program and pursuing named-patient access and an eventual EU licensing partner rather than direct EU commercialization — a meaningful narrowing of YARTEMLEA's near-term addressable market outside the U.S.
• Single-product commercial concentration: Virtually all of Omeros's near-term revenue growth depends on one drug (YARTEMLEA) in one narrow indication; any U.S. reimbursement, competitive, or safety setback would disproportionately affect the company.
• Thin absolute cash base despite the inflection: Cash and short-term investments stood at roughly $132 million as of mid-2026 — healthy relative to the company's improved cash generation and incoming OMIDRIA/Novo Nordisk milestones, but still modest in absolute terms for a company funding its own U.S. commercial launch, continued pipeline R&D, and potential EU licensing negotiations.
• Future competition in TA-TMA itself: If AstraZeneca's ravulizumab Phase 3 adult TA-TMA results read out positively, YARTEMLEA's currently uncontested position could erode.
• Reliance on partner execution for zaltenibart economics: The bulk of zaltenibart's ~$1.8 billion in potential milestone value depends entirely on Novo Nordisk's execution of a global Phase 3 PNH program that Omeros no longer controls.

---

6. Financial Overview

---

7. Summary Conclusion

Omeros has executed a rare pivot for a small-cap biopharma: converting roughly two decades of complement-pathway research into both a commercial, first-in-class orphan drug (YARTEMLEA in TA-TMA) and a near-$2 billion pharma partnership (zaltenibart with Novo Nordisk) within the same several-month window, turning a company that not long ago faced real liquidity pressure into one reporting GAAP net income with over $130 million in cash. The core investment and operating tension going forward is geographic and competitive: Omeros's U.S. position in TA-TMA is currently uncontested and highly defensible, but its European opportunity has hit a real regulatory wall with the CHMP's negative opinion, and its broader complement franchise beyond narsoplimab now depends on a partner's (Novo Nordisk's) execution rather than its own. How quickly YARTEMLEA's U.S. launch scales, and whether Omeros can still secure EU access through a licensing partner, will determine whether this inflection compounds into durable profitability or proves to be a one-time cash event riding on a single narrow-indication drug.